Venus Remedies Ltd

Venus Remedies Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Venus Remedies Ltd

₹ 700 1.29%
21 Nov 2:54 p.m.
venusremedies.com BSE: 526953 NSE: VENUSREM
About

Incorporated in 1989, Venus Remedies
Ltd is a research based pharmaceutical company and an injectable manufacturer[1]

Key Points

Business Overview:[1][2]
VSR is one of the largest manufacturers of meropenem antibiotics and emerging player in AMR drug in India. It offers a wide range of pharmaceutical products that cater to various therapeutic areas, including anti infective (antibiotics), antimicrobial resistance, oncology, neurology, pain management, skin
& wound care. Company has 1040+ marketing authorizations globally, 135+ patents and 180+ product basket which includes formulations such as injectables,
tablets, and topical preparations

Website BSE NSE
  • Market Cap ₹ 935 Cr.
  • Current Price ₹ 700
  • High / Low ₹ 723 / 270
  • Stock P/E 14.7
  • Book Value ₹ 445
  • Dividend Yield 0.00 %
  • ROCE 11.1 %
  • ROE 7.16 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.

Cons

  • Though the company is reporting repeated profits, it is not paying out dividend
  • Company has a low return on equity of 6.37% over last 3 years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
140 117 156 95 168 143 195 109 170 177 195 137 193
127 109 131 85 150 131 176 97 163 158 166 122 162
Operating Profit 13 8 25 10 18 12 19 11 8 18 29 15 31
OPM % 9% 7% 16% 11% 11% 8% 10% 10% 4% 10% 15% 11% 16%
2 4 3 2 3 2 4 2 8 12 7 3 2
Interest 0 0 0 0 0 0 0 0 0 0 0 0 0
Depreciation 9 7 8 8 6 7 6 6 6 5 5 6 6
Profit before tax 6 5 20 5 14 8 17 7 9 25 31 13 26
Tax % 8% 28% 44% 77% 31% 12% 40% 82% 61% 21% 32% 24% 24%
5 3 11 1 10 7 11 1 4 20 21 10 20
EPS in Rs 3.99 2.46 8.27 0.88 7.44 5.12 7.86 0.91 2.63 14.66 15.71 7.18 15.06
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
531 455 407 400 372 322 335 544 597 552 596 640 702
393 366 326 349 333 289 295 490 535 492 537 577 608
Operating Profit 138 89 81 51 39 33 41 54 62 60 60 64 94
OPM % 26% 20% 20% 13% 11% 10% 12% 10% 10% 11% 10% 10% 13%
0 1 2 2 2 -3 -4 43 8 10 12 31 24
Interest 29 41 38 34 35 25 13 13 0 0 0 0 0
Depreciation 40 46 42 40 34 34 32 35 34 32 26 23 22
Profit before tax 69 3 4 -22 -28 -30 -8 49 36 38 45 72 95
Tax % 7% -95% 52% -21% 11% -4% 24% -27% -12% 30% 36% 37%
64 5 2 -17 -31 -29 -10 62 41 27 28 45 70
EPS in Rs 56.20 4.51 1.49 -13.84 -24.87 -23.15 -8.10 50.05 30.46 19.88 21.31 33.90 52.61
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 3%
5 Years: 14%
3 Years: 2%
TTM: 14%
Compounded Profit Growth
10 Years: 22%
5 Years: 69%
3 Years: -3%
TTM: 187%
Stock Price CAGR
10 Years: 19%
5 Years: 40%
3 Years: 54%
1 Year: 131%
Return on Equity
10 Years: 2%
5 Years: 8%
3 Years: 6%
Last Year: 7%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 11 11 11 12 12 12 12 12 13 13 13 13 13
Reserves 450 445 426 376 350 320 311 388 427 447 474 548 581
289 321 335 312 307 298 220 51 43 42 41 2 14
84 64 70 65 82 102 100 104 97 98 98 153 159
Total Liabilities 834 841 843 765 751 733 644 556 580 601 627 716 768
439 444 452 406 389 364 289 262 241 216 219 229 237
CWIP 68 78 80 66 65 65 25 25 25 26 21 26 34
Investments 0 0 0 0 0 0 0 0 0 20 19 84 193
327 319 310 293 297 304 330 269 314 339 368 376 303
Total Assets 834 841 843 765 751 733 644 556 580 601 627 716 768

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
53 68 47 59 31 45 78 132 41 37 37 86
-95 -67 3 -18 8 -11 -5 57 -17 -58 -8 -77
40 -1 -46 -44 -39 -35 -73 -162 -9 -1 -1 -1
Net Cash Flow -2 -1 3 -4 0 -1 -0 27 14 -22 28 9

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 45 51 55 43 46 43 33 21 24 51 49 64
Inventory Days 173 194 219 226 246 286 296 129 118 132 125 97
Days Payable 38 40 38 48 52 72 77 76 47 56 55 89
Cash Conversion Cycle 180 204 236 221 240 257 252 74 95 127 120 72
Working Capital Days 39 54 69 54 25 -1 73 71 82 109 118 86
ROCE % 14% 6% 5% 2% 1% 1% 2% 8% 8% 8% 9% 11%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76% 41.76%
1.07% 1.00% 0.98% 1.03% 1.59% 1.48% 1.06% 1.18% 1.11% 1.34% 2.25% 1.86%
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.11% 0.75%
57.19% 57.26% 57.26% 57.21% 56.65% 56.76% 57.17% 57.06% 57.13% 56.90% 55.89% 55.62%
No. of Shareholders 22,24321,71920,49819,26719,56019,91319,61419,55719,77119,98219,30717,725

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings